Continuous Glucose Monitoring for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if continuous glucose monitoring (CGM) can help individuals with glioblastoma, a type of brain cancer, better manage their blood sugar levels. High blood sugar during treatment has been linked to worse outcomes, and CGM might help detect and manage these spikes early. The trial compares two groups: one using CGM with additional guidance and another using regular glucose checks. Suitable participants have been newly diagnosed with glioblastoma based on brain scans and can use the CGM device and attend dietary counseling. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could improve treatment outcomes for glioblastoma.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What prior data suggests that continuous glucose monitoring is safe for glioblastoma patients?
Research shows that continuous glucose monitoring (CGM) helps people with diabetes track their blood sugar levels. Previous studies have demonstrated that this technology aids in more effective glucose management. CGM uses a small sensor placed under the skin to regularly check glucose levels.
Regarding safety, CGM is generally well-tolerated by people with diabetes, with few reports of serious side effects. Some users might experience minor skin irritation at the sensor site, but serious issues are rare.
This trial explores whether CGM can help patients with glioblastoma, a type of brain cancer, manage their blood sugar levels. Stabilizing these levels might improve survival rates for these patients.
While specific data on CGM use in brain cancer patients is lacking, its established use in diabetes suggests it is safe for many people. This trial seeks to determine if it can also benefit those with brain cancer.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores the potential benefits of continuous glucose monitoring (CGM) for brain cancer patients, a method that hasn't been widely used in this context before. Unlike the standard intermittent glucose monitoring, CGM provides real-time data on glucose levels, allowing for more precise management and timely endocrinology-guided interventions. This could lead to better overall patient outcomes, as it offers a more comprehensive view of a patient's glucose trends and potential responses to treatment. Additionally, the incorporation of dietary counseling aims to further support patients by optimizing nutritional intake, which is a crucial aspect of cancer care.
What evidence suggests that continuous glucose monitoring is effective for managing glucose levels in glioblastoma patients?
Research has shown that maintaining blood sugar levels is crucial for glioblastoma patients. High blood sugar during treatment correlates with worse survival rates. Studies have found that continuous glucose monitoring (CGM) helps track blood sugar levels in real time, enabling quicker intervention if necessary. In this trial, some participants will receive standard of care (SOC) treatment plus CGM, potentially aiding in the detection and management of blood sugar spikes. A review of over 2,000 brain tumor patients confirmed that high blood sugar significantly reduces overall survival. By using CGM, glioblastoma patients might better control their blood sugar, potentially improving their survival chances.12367
Who Is on the Research Team?
Gelareh Zadeh, MD, PhD
Principal Investigator
Mayo Clinic in Rochester
Are You a Good Fit for This Trial?
This trial is for adults with glioblastoma, a type of brain cancer. It's focused on those who may have high blood sugar due to their treatment. Participants should be able to use a continuous glucose monitoring device and follow the study procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive SOC treatment plus either continuous glucose monitoring (CGM) or intermittent glucose monitoring for up to 52 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Continuous Glucose Monitoring
Trial Overview
The study tests if using continuous glucose monitoring can help manage blood sugar levels in glioblastoma patients, potentially improving survival. It includes dietary interventions, regular MRI scans, biospecimen collection for research, and questionnaires about health.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients receive SOC treatment plus CGM with endocrinology-guided interventions as needed and attend dietary counseling sessions once a month for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the trial.
Patients receive SOC treatment plus intermittent glucose monitoring as clinically indicated for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the trial.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Citations
Continuous Glucose Monitoring for Brain Cancer
This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) ...
Assessing the effectiveness of continuous glucose monitoring ...
Exploratory outcomes are overall postoperative infection rate, MACE rate, brain damage (eg, delirium and stroke) and length of hospital stay ...
Rewiring of cortical glucose metabolism fuels human brain ...
How brain cancers rewire glucose use to drive aggressive growth remains unclear. Here we infused 13C-labelled glucose into patients and mice ...
Metabolic imbalance and brain tumors: The interlinking ...
A meta-analysis encompassing 7 studies with > 2000 brain tumor patients confirmed this link, showing that hyperglycemia significantly reduces overall survival [ ...
Continuous Glucose Monitoring for the Management of ...
This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) ...
USE OF A CONTINUOUS GLUCOSE MONITOR FOR ...
We describe a case of a 55-year-old female with hypoglycemia unawareness and seizures diagnosed with proinsulinoma. She utilized an intermittently scanned ...
Impact of glycemia on survival of glioblastoma patients ...
This study demonstrates and validates that glycemia is an independent predictor for survival in GB patients treated with RT and TMZ.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.